PT  - JOURNAL ARTICLE
AU  - Dragana Jovanovic
AU  - Nevana Secan
AU  - Zafir Murtezani
AU  - Milan Rancic
AU  - Vesna Kacar-Kukric
AU  - Marta Velinovic
AU  - Ana Tepavac
AU  - Evica Budisin
AU  - Zoran Andric
AU  - Nevena Vukobradovic Djoric
TI  - Analysis of clinicopathological characteristics of 982 lung cancer patients and subsequent treatment - Epidemiology study
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P4535
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P4535.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P4535.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - The purpose of the survey was the analysis of clinicopathological features of lung cancer patients in Serbia and subsequent treatment approach.Method: the data were collected based on specific questionnaire at 4 major centers in Serbia.Results. Out of 982 patients (pts), NSCLC was diagnosed in 80% (789), 71.6% (679) in stage IIIb and IV. Most common histological subtype was adenocarcinoma (46%), followed by squamous cell carcinoma (44%). Neodjuvant therapy was applied in 8% (67pts), while 19% (153pts) were operated - 64% (98) of operated patients recieved adjuvant chemotherapy. Among IIIb/IV NSCLC patients, 91% (511) recieved 1st line chemotherapy, platinum/etoposide (51%) and platinum/gemcitabine (45%) most frequently applied regimens. Second line chemotherapy was given to 27% (136) of 1st line treated patients. Third line chemotherapy was applied in 22% (29) of 2nd line treated patients.Conclusions. This is the largest series of lung cancer patients in Serbia, analized by both, patient characteristics and treatment. Compared to previous similar NSCLC analysis in 2009, the number of NSCLC patients is obviously increasing (1.5% per year). Rate of adenocarcinoma is also increasing (41% in 2009 vs 45% in 2011). Regarding treatment options, there is no significant difference.